Cipla Limited

CIPLA

INE059A01026

Cipla specializes in development, manufacturing and marketing of pharmaceutical products. The group provides prescription products and OTC medicines for the treatment of cardiovascular, ophthalmic and dermatological diseases, respiratory troubles, cancers, allergies, infections etc. Besides, Cipla develops and sells veterinary products. Net sales by source of income break down between sale of products (96.9%) and services (3.1%). Net sales are distributed geographically as follows: India (39.4%), the United States (18.5%), South Africa (17%) and other (25.1%).

Sector

Pharmaceuticals

Calendar

15/05/2024 - Non-Deal Roadshow

Related indices

NIFTY 50 , NIFTY 100

More about the company

Income Statement Evolution

More financial data

Ratings for Cipla Limited

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1,340 INR

Average target price

1,461 INR

Spread / Average Target

+9.04%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
CIPLA LIMITED	+13.82%	12.95B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+20.52%	43.27B
OTSUKA HOLDINGS CO., LTD.	+25.28%	22.92B
SANDOZ GROUP AG	+19.25%	15.43B
ZYDUS LIFESCIENCES LIMITED	+44.30%	11.83B
ONO PHARMACEUTICAL CO., LTD.	-7.79%	6.91B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+13.13%	5.55B
RICHTER GEDEON VEGYÉSZETI GYÁR NYILVÁNOSAN MUKÖDO RT.	+9.14%	4.9B

Generic Pharmaceuticals

Delayed NSE India S.E. Other stock markets 01:03:24 13/05/2024 pm IST			5-day change	1st Jan Change
1,419 ^INR	+5.92%		-0.44%	+13.82%

09:31am	Jefferies Adjusts Cipla’s Price Target to INR1,400 From INR1,250, Keeps at Hold	MT
08:28am	Cipla's Consolidated Net Profit Climbs in Fiscal Q4; Shares Up 6%	MT

Jefferies Adjusts Cipla’s Price Target to INR1,400 From INR1,250, Keeps at Hold	01:01pm	MT
Cipla's Consolidated Net Profit Climbs in Fiscal Q4; Shares Up 6%	11:58am	MT
INDIA STOCKS-Election worries, foreign selling spook Indian equities; volatility climbs	10:54am	RE
INDIA STOCKS-Indian shares fall as Tata Motors slides; inflation data awaited	09:49am	RE
Transcript : Cipla Limited, Q4 2024 Earnings Call, May 10, 2024	10/05
Market Heavyweights Lifts Indian Equities to End Week Higher	10/05	MT
India's Cipla open to partnering with Eli Lilly to market their obesity drugs, CEO says	10/05	RE
India's Cipla beats Q4 profit estimates	10/05	RE
Cipla Limited Recommends Payment of Final Dividend for the Financial Year Ended March 31, 2024	10/05	CI
Cipla Limited Announces Retirement of S. Radhakrishnan as Non-Executive Director	10/05	CI
Cipla Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	10/05	CI
India's Alembic Pharma posts higher Q4 profit on strong N.America sales	09/05	RE
Indian Equities Settle Flat on Wednesday, Dragged by Banks, FMCG Stocks	08/05	MT
Cipla Gets Single Observation from US FDA After Kurkumbh, India Unit Inspection	08/05	MT
Indian shares set to open higher on Fed rate-cut hopes	06/05	RE
Cipla Limited Receives an Order Passed by the GST Authority	29/04	CI
Cipla Arm Completes Acquisition of Ivia's Cosmetics, Personal-Care Marketing Business	29/04	MT
Indian Equities End Higher Midweek as Iran-Israel Conflict Subsides	24/04	MT
Cipla Limited Receives Order from the GST Authority	19/04	CI
India's Biocon developing its own version of Wegovy, clinical trial likely next year	18/04	RE
Cipla's Consumer Healthcare Arm to Acquire Ivia's Cosmetics, Personal-Care Marketing Business	16/04	MT
Indian Equities End Higher on Wednesday, Lifted Mainly by Metal Stocks	10/04	MT
Cipla Receives US FDA Observations Following Patalganga Facility Inspection	05/04	MT
Cipla Gets Regulatory Nod to Merge US-Based Subsidiaries	27/03	MT
Cipla to Distribute Sanofi's CNS Product Line in India	27/03	MT